Adjuvant sunitinib for high-risk-resected renal cell carcinoma: a meta-analysis of ASSURE and S-TRAC trials

被引：13
|
作者：
Gyawali, B. [1 ]
Ando, Y. [1 ]
机构：
[1] Nagoya Univ, Grad Sch Med, Dept Clin Oncol & Chemotherapy, Nagoya, Aichi, Japan
来源：
ANNALS OF ONCOLOGY | 2017年 / 28卷 / 04期
关键词：
D O I：
10.1093/annonc/mdw667
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：898 / 899
页数：2
相关论文
共 50 条
  • [1] ADJUVANT SUNITINIB IN PATIENTS WITH HIGH RISK RENAL CELL CARCINOMA: SUBGROUP ANALYSES FROM S-TRAC TRIAL
    Pantuck, Allan
    Patard, Jean-Jacques
    Patel, Anup
    Ravaud, Alain
    Motzer, Robert J.
    Pandha, Hardev S.
    George, Daniel J.
    Chang, Yen-Hwa
    Escudier, Bernard
    Donskov, Frede
    Magheli, Ahmed
    Carteni, Giacomo
    Laguerre, Brigitte
    Tomczak, Piotr
    Breza, Jan
    Gerletti, Paola
    Lechuga, Mariajose
    Lin, Xun
    Casey, Michelle
    Staehler, Michael
    JOURNAL OF UROLOGY, 2017, 197 (04): : E62 - E63
  • [2] Understanding the adverse event experience in the S-TRAC adjuvant trial of sunitinib for high-risk renal cell carcinoma
    Wood, Sarah Yenser
    Ryan, Joanne C.
    Clair, Andrew G.
    George, Daniel J.
    FUTURE ONCOLOGY, 2020, 16 (04) : 39 - 47
  • [3] S-TRAC: UNDERSTANDING THE ADVERSE EVENT (AE) EXPERIENCE IN THE ADJUVANT TRIAL OF SUNITINIB FOR HIGH RISK RENAL CELL CARCINOMA (RCC)
    Wood, Sarah Yenser
    Ryan, Joanne C.
    Clair, Andrew G.
    George, Daniel
    ONCOLOGY NURSING FORUM, 2018, 45 (02)
  • [4] Adjuvant sunitinib (SU) in patients (pts) with high risk renal cell carcinoma (RCC): Safety and therapy management in S-TRAC trial
    Staehler, M.
    Motzer, R. J.
    George, D. J.
    Pandha, H. S.
    Donskov, F.
    Escudier, B.
    Kliment, J.
    Pantuck, A. J.
    Patel, A.
    Deannuntis, L.
    Bhattacharyya, H.
    Lin, X.
    Lechuga, M.
    Serfass, L.
    Patard, J-J.
    Ravaud, A.
    ANNALS OF ONCOLOGY, 2017, 28
  • [5] Sunitinib as adjuvant treatment in subjects with high risk renal cell carcinoma - A randomized double-blind phase 3 study (s-trac)
    Staehler, M.
    Roigas, J.
    ONKOLOGIE, 2008, 31 : 186 - 186
  • [6] Adjuvant sunitinib in patients with high-risk renal cell carcinoma: safety, therapy management, and patient-reported outcomes in the S-TRAC trial
    Staehler, M.
    Motzer, R. J.
    George, D. J.
    Pandha, H. S.
    Donskov, F.
    Escudier, B.
    Pantuck, A. J.
    Patel, A.
    DeAnnuntis, L.
    Bhattacharyya, H.
    Ramaswamy, K.
    Zanotti, G.
    Lin, X.
    Lechuga, M.
    Serfass, L.
    Paty, J.
    Ravaud, A.
    ANNALS OF ONCOLOGY, 2018, 29 (10) : 2098 - 2104
  • [7] Phase III trial of sunitinib (SU) vs placebo (PBO) as adjuvant treatment for high-risk renal cell carcinoma (RCC) after nephrectomy (S-TRAC)
    Ravaud, A.
    Motzer, R. J.
    Pandha, H. S.
    Staehler, M.
    George, D.
    Pantuck, A. J.
    Patel, A.
    Chang, Y-H.
    Escudier, B.
    Donskov, F.
    Magheli, A.
    Carteni, G.
    Laguerre, B.
    Tomczak, P.
    Breza, J.
    Gerletti, P.
    Lin, X.
    Lechuga, M.
    Martini, J-F.
    Patard, J-J.
    ANNALS OF ONCOLOGY, 2016, 27
  • [8] SUNITINIB TREATMENT OF RENAL ADJUVANT CANCER (S-TRAC): A RANDOMIZED, DOUBLE-BLIND, PHASE III STUDY OF SUNITINIB VS. PLACEBO IN SUBJECTS AT HIGH RISK OF RECURRENT RENAL CELL CARCINOMA (RCC)
    Ravaud, A.
    Motzer, R. J.
    Pandha, H.
    Staehler, M.
    George, D. J.
    Pantuck, A.
    Patel, A.
    Gerletti, P.
    Chen, L.
    Patard, J.
    ANNALS OF ONCOLOGY, 2012, 23 : 292 - 293
  • [9] Immune Biomarkers Predictive for Disease-Free Survival with Adjuvant Sunitinib in High-Risk Locoregional Renal Cell Carcinoma: From Randomized Phase III S-TRAC Study
    George, Daniel J.
    Martini, Jean-Francois
    Staehler, Michael
    Motzer, Robert J.
    Magheli, Ahmed
    Escudier, Bernard
    Gerletti, Paola
    Li, Sherry
    Casey, Michelle
    Laguerre, Brigitte
    Pandha, Hardev S.
    Pantuck, Allan J.
    Patel, Anup
    Lechuga, Maria J.
    Ravaud, Alain
    CLINICAL CANCER RESEARCH, 2018, 24 (07) : 1554 - 1561
  • [10] Adjuvant Treatment for Resected Renal Cell Carcinoma (RCC): Are All Strategies Equally Negative? Meta-analysis of Randomized Trials (RCTs)
    Massari, F.
    Bria, E.
    Giannarelli, D.
    Milella, M.
    Cognetti, F.
    Tortora, G.
    Pappagallo, G.
    Porta, C.
    EUROPEAN JOURNAL OF CANCER, 2011, 47 : S524 - S525
12345